Alnylam Pharmaceuticals, Inc. (ALNY) Misses Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $146.07 +0.19%
EPS Growth %: -7.5%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
SEIC, OSBC, USAP, More
EPS Growth %: -7.5%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
SEIC, OSBC, USAP, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.63), $0.07 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $9.36 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
- Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance
- Orange shares down despite reporting in-line core operating profit in Q1
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
